» Articles » PMID: 31770409

Clade F AAVHSCs Cross the Blood Brain Barrier and Transduce the Central Nervous System in Addition to Peripheral Tissues Following Intravenous Administration in Nonhuman Primates

Overview
Journal PLoS One
Date 2019 Nov 27
PMID 31770409
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

The biodistribution of AAVHSC7, AAVHSC15, and AAVHSC17 following systemic delivery was assessed in cynomolgus macaques (Macaca fascicularis). Animals received a single intravenous (IV) injection of a self-complementary AAVHSC-enhanced green fluorescent protein (eGFP) vector and tissues were harvested at two weeks post-dose for anti-eGFP immunohistochemistry and vector genome analyses. IV delivery of AAVHSC vectors produced widespread distribution of eGFP staining in glial cells throughout the central nervous system, with the highest levels seen in the pons and lateral geniculate nuclei (LGN). eGFP-positive neurons were also observed throughout the central and peripheral nervous systems for all three AAVHSC vectors including brain, spinal cord, and dorsal root ganglia (DRG) with staining evident in neuronal cell bodies, axons and dendritic arborizations. Co-labeling of sections from brain, spinal cord, and DRG with anti-eGFP antibodies and cell-specific markers confirmed eGFP-staining in neurons and glia, including protoplasmic and fibrous astrocytes and oligodendrocytes. For all capsids tested, 50 to 70% of glial cells (S100-β+) and on average 8% of neurons (NeuroTrace+) in the LGN were positive for eGFP expression. In the DRG, 45 to 62% of neurons and 8 to 12% of satellite cells were eGFP-positive for the capsids tested. eGFP staining was also observed in peripheral tissues with abundant staining in hepatocytes, skeletal- and cardio-myocytes and in acinar cells of the pancreas. Biodistribution of AAVHSC vector genomes in the central and peripheral organs generally correlated with eGFP staining and were highest in the liver for all AAVHSC vectors tested. These data demonstrate that AAVHSCs have broad tissue tropism and cross the blood-nerve and blood-brain-barriers following systemic delivery in nonhuman primates, making them suitable gene editing or gene transfer vectors for therapeutic application in human genetic diseases.

Citing Articles

Brain-targeting drug delivery systems: The state of the art in treatment of glioblastoma.

Sun B, Li R, Ji N, Liu H, Wang H, Chen C Mater Today Bio. 2025; 30:101443.

PMID: 39866779 PMC: 11759563. DOI: 10.1016/j.mtbio.2025.101443.


Adeno-associated Virus-Mediated Gene Delivery Across the Blood-Brain Barrier.

Yao Y, Bei F Adv Neurobiol. 2024; 41:91-112.

PMID: 39589711 DOI: 10.1007/978-3-031-69188-1_4.


Nuclease-free precise genome editing corrects MECP2 mutations associated with Rett syndrome.

Bijlani S, Pang K, Bugga L, Rangasamy S, Narayanan V, Chatterjee S Front Genome Ed. 2024; 6:1346781.

PMID: 38495533 PMC: 10940404. DOI: 10.3389/fgeed.2024.1346781.


A novel dual-plasmid platform provides scalable transfection yielding improved productivity and packaging across multiple AAV serotypes and genomes.

van Lieshout L, Rubin M, Costa-Grant K, Ota S, Golebiowski D, Panico T Mol Ther Methods Clin Dev. 2023; 29:426-436.

PMID: 37273900 PMC: 10238442. DOI: 10.1016/j.omtm.2023.05.004.


Single Systemic Administration of a Gene Therapy Leading to Disease Treatment in Metachromatic Leukodystrophy Knock-Out Mice.

St Martin T, Seabrook T, Gall K, Newman J, Avila N, Hayes A J Neurosci. 2023; 43(19):3567-3581.

PMID: 36977578 PMC: 10184740. DOI: 10.1523/JNEUROSCI.1829-22.2023.


References
1.
Penaud-Budloo M, Francois A, Clement N, Ayuso E . Pharmacology of Recombinant Adeno-associated Virus Production. Mol Ther Methods Clin Dev. 2018; 8:166-180. PMC: 5908265. DOI: 10.1016/j.omtm.2018.01.002. View

2.
Hudry E, Andres-Mateos E, Lerner E, Volak A, Cohen O, Hyman B . Efficient Gene Transfer to the Central Nervous System by Single-Stranded Anc80L65. Mol Ther Methods Clin Dev. 2018; 10:197-209. PMC: 6083902. DOI: 10.1016/j.omtm.2018.07.006. View

3.
Simonelli F, Maguire A, Testa F, Pierce E, Mingozzi F, Bennicelli J . Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther. 2009; 18(3):643-50. PMC: 2839440. DOI: 10.1038/mt.2009.277. View

4.
Saraiva J, Nobre R, de Almeida L . Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9. J Control Release. 2016; 241:94-109. DOI: 10.1016/j.jconrel.2016.09.011. View

5.
Patricio M, Barnard A, Xue K, MacLaren R . Choroideremia: molecular mechanisms and development of AAV gene therapy. Expert Opin Biol Ther. 2018; 18(7):807-820. DOI: 10.1080/14712598.2018.1484448. View